$RXII #RXI Pharmaceuticals Corp Update: Spotlight on cosmetic product...
RXi Pharmaceuticals (RXi) continues to make solid progress with its development pipeline. We anticipate one of two promising cosmeceutical candidates to enter human testing this year, moving forward on...
View Article$RXII #RXI Pharmaceuticals Corp Initiation: Delivering on its self-delivering...
Over the past year, RXi Pharmaceuticals (RXi) has made significant headway with its pipeline as well as in securing partnerships. Its lead compound RXI-109 is in Phase II in dermatological scarring and...
View Article$RXII #RXI Pharmaceuticals Corp Update: Samcyprone data at AAD
At the American Academy of Dermatology (AAD) Summer Meeting, data from a pilot study of Samcyprone (diphenylcyclopropenone ointment) in the treatment of common warts was presented. Overall, 38.1% of...
View Article$RXII #RXI Pharmaceuticals Corp Expanding into immuno-oncology
RXi recently announced that it has entered into an exclusive option agreement to acquire MirImmune, an early-stage private company focusing on immune checkpoint modulation, in exchange for a share...
View Article
